Pfizer shares the ADC data that convinced it to start a Phase 3 lung cancer trial

Lei Lei Wu

News Reporter

When Pfizer laid out the ambitious vision for its new oncology division in February, it announced that it was taking the antibody-drug conjugate sigvotatug vedotin …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pfizer shares the ADC data that convinced it to start a Phase 3 lung cancer trial

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Associate Director, Market Insights and Analytics

Celldex Therapeutics

Hampton, NJ, USA

Autoimmune CAR-T data dump: Kyverna, Cabaletta shares fall after unveiling early-stage results

Stephen Squinto talks writing checks and next-gen obesity drugs as JP Morgan closes first $500M+ biotech fund

Updated: Telix Pharmaceuticals pulls Nasdaq listing plans just before trading was to start

Gilead cancer drug magrolimab showed worrying trends around death

Nurix’s protein degrader overcomes resistance to BTK mutations in small leukemia study

De-risking the patient journey in cell therapies: Six key considerations

Pfiz­er shares the ADC da­ta that con­vinced it to start a Phase 3 lung can­cer tri­al

News Reporter

Sign up to read this article for free.

Celldex Therapeutics

Hampton, NJ, USA

Pfizer shares the ADC data that convinced it to start a Phase 3 lung cancer trial